ArticleDiagnostics (Basel, Switzerland)2021
Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBD
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Double-Antibody Sandwich Enzyme-Linked Immunosorbent Assay for Detecting Feline Coronavirus Infection.Veterinary medicine and science · 2026Article
- Expression, Purification, and Application of SARS-CoV-2 Nucleocapsid Protein for Serological Detection of IgG and IgM Antibodies.Avicenna journal of medical biotechnology · 2026Article
- Expression and purification of SARS-CoV-2 receptor binding domain inResearch in pharmaceutical sciences · 2024Article
- Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in Escherichia coli for the Development of Neutralizing Antibody Assay.Molecular biotechnology · 2023Article
- Antigenicity and immunogenicity of SARS-CoV-2 surface glycoprotein fragment in CHO cells.Iranian journal of microbiology · 2023Article
- Article
- Current trends in COVID-19 diagnosis and its new variants in physiological fluids: Surface antigens, antibodies, nucleic acids, and RNA sequencing.Trends in analytical chemistry : TRAC · 2022Review
- A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan.International journal of biological macromolecules · 2022Article
- Methylene Blue functionalized carbon nanodots combined with different shape gold nanostructures for sensitive and selective SARS-CoV-2 sensing.Sensors and actuators. B, Chemical · 2022Article
- A magnetic bead immunoassay to detect high affinity human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in Escherichia coli.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Addition of arginine hydrochloride and proline to the culture medium enhances recombinant protein expression in Brevibacillus choshinensis: The case of RBD of SARS-CoV-2 spike protein and its antibody.Protein expression and purification · 2022Article
- Article
- Automated ELISA On-Chip for the Detection of Anti-SARS-CoV-2 Antibodies.Sensors (Basel, Switzerland) · 2021Article
- Expression of SARS-CoV-2 surface glycoprotein fragment 319-640 in E. coli, and its refolding and purification.Protein expression and purification · 2021Article
- Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein fromEngineering in life sciences · 2021Article
- Designing and Expression of Recombinant Chimeric Spike Protein from SARS-CoV-2 inIranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Massive worldwide serological testing for SARS-CoV-2 is needed to determine the extent of virus exposure in a particular region, the ratio of symptomatic to asymptomatic infected persons, and the duration and extent of immunity after infection. To achieve this, the development and production of reliable and cost-effective SARS-CoV-2 antigens is critical. We report the bacterial production of the peptide S-RBD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.